


Distribution of 232 miRNAs in known transcription units (TUs)


Hsa-mir-7b: exon, non-coding mRNA



Hsa-mir-7d: intron, non-coding mRNA




Intron/exon of non-coding genes 66, 28%



76, 33%
Separate TUs

Intron of coding genes 90, 39%

Hsa-mir-126: intron, coding mRNA






Identification of Mammalian microRNA Host Genes and Transcription Units

Antony Rodriguez, Sam Griffiths-Jones, Jennifer L. Ashurst and Allan Bradley

Genome Res. 2004 14: 1902-1910; originally published online Sep 13, 2004; doi:10.1101/gr.2722704

Possible processing steps of intronic miRNAs from a common primary host gene transcript



Host gene and intronic miRNA expression in leukemic cell lines

Background

- correlation between host genes and intronic miRNA expression has been reported for reference normal tissue

Methods and Results

- total RNA from NB4 (acute promyelocytic) and AML2 (acute myeloid) leukemia cell lines was hybridized to U133A Affymetrix gene chips as well as to a miRNA microarray
- Host genes and intronic miRNA expression was measured and compared between the two platforms for each cell line

Intronic miRNAs and host gene co-expression in reference normal tissue

TABLE 1. Correlation between expression of intronic miRNAs and host gene

Gene name	Ensembl ID ^a	MicroRNA	Host gene corr.	Upstream corr.	Downstream corr.
<i>CROC4</i>	125462	hsa-miR-9-1	0.999	0.083	-0.054
<i>PDE2A</i>	186642	hsa-miR-139	0.99	-0.293	0.493
<i>C20orf166</i>	174407	hsa-miR-133a-2	0.988	-0.105	0.185
		hsa-miR-1-1	0.968	-0.045	0.226
<i>PGSF1</i>	176840	hsa-miR-7-3	0.961	-0.394	-0.123
<i>ABLIM2</i>	163995	hsa-miR-95	0.96	-0.302	-0.089
<i>LOC254559</i>	LOC254559	hsa-miR-9-3	0.95	-0.122	-0.150
<i>AATYK</i>	181409	hsa-miR-338	0.921	0.906	-0.123
<i>EGFL7</i>	172889	hsa-miR-126	0.888	0.727	-0.246
<i>R3HDM</i>	48991	hsa-miR-128a	0.856	-0.037	-0.363
<i>MCM7^b</i>	166508	hsa-miR-25	0.838	-0.548	-0.377

TABLE 1. Correlation between expression of intronic miRNAs and host gene

Gene name	Ensembl ID ^a	MicroRNA	Host gene corr.	Upstream corr.	Downstream corr.
<i>TRPM3</i>	83067	hsa-miR-204	0.796	-0.047	-0.240
<i>TLN2</i>	171914	hsa-miR-190	0.663	-0.269	-0.172
<i>PANK3</i>	120137	hsa-miR-103-1	0.638	-0.203	0.079
<i>PTPRN</i>	54356	hsa-miR-153-1	0.626	0.579	-0.178
<i>CTDSP2</i>	175215	hsa-miR-26a-2	0.609	0.492	0.265
<i>SMC4L1</i>	113810	hsa-miR-15b	0.509	-0.134	-0.098
		hsa-miR-16-2	0.504	-0.128	-0.021
<i>UREB1</i>	86758	hsa-miR-98	0.503	-0.209	-0.512
		hsa-let-7f-2	0.379	-0.242	-0.194


RNA

Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes

SCOTT BASKERVILLE and DAVID P. BARTEL

RNA 2005 11: 241-247
doi:10.1261/ma.7240905

Co-expression of host genes (top) and intronic miRNAs (bottom)



Summary of findings:co-expression of host genes and intronic miRNAs in cell lines

miRNA	Host	Chr	LOCATION	ENSEMBLE
hsa-mir-103-2	PANK2	20	3893141-3893218	ENSG00000125779
hsa-mir-128a	R3HDM1	2	136633736-136633817	ENSG00000048991
hsa-mir-15b	SMC4L1	3	161443289-161443386	ENSG00000113810
hsa-mir-25	MCM7	7	99302663-99302580	ENSG00000166508
hsa-mir-26b	CTDSP1	2	219469909-219469985	ENSG00000144579

Up-regulation of host genes and intronic miRNAs by aberrantly-expressed transcription factors


Background

- De-regulation of miRNA expression could be caused by copy number polymorphisms (CNP) or abnormal expression of transcription factors (TF) (e.g. *c-myc*)
- Lyl1 is a basic helix-loop-helix TF and suspected oncoprotein that is over-expressed in AML and T-ALL
- Lyl1 Binds to Ebox promoter DNA
- Lyl1 over-expression is associated with poor prognosis



Methods and Results

- HA-Lyl1 or empty vector expression was enforced in K562 cells
- Host gene and miRNA expression were determined by microarrays

Over-expressed Ly1 up-regulates intronic miRNA expression in K562 cells




Genomic features of PANK1 and PANK2 host genes and mirs-107 and 103-2 up-regulated by Lyl1




- PANK2 deficiency caused by loss of enzymatic activity due to mutation is implicated in neurodegeneration with Brain Iron Accumulation Type1 Syndrome (Hallewvorden-Spatz)

PANTOTHENATE AND CoA BIOSYNTHESIS




Lyl1 binding sites in conserved EGFL7 and PANK1 proximal promoters of mir-126 and mir-107



Lyl1-E47 binding site

Pos	Strand	Core	Matrix	Sequence
7	(-)	0.886	0.852	cccatCACCTgctgcc



Lyl1-E47 binding site

Pos	Strand	Core	Matrix	Sequence
17	(+)	1.000	0.925	cgctgcaTCTGGccca

Functional meta-analysis of intronic miRNAs


Background

- intronic miRNAs and host genes are differentially-expressed in tumors
- therefore the percentage of differentially expressed miRNA targets should also show tissue specificity
- if intronic miRNAs are co-ordinately expressed with their host genes the patterns of miRNA target gene expression should follow those of the miRNA host genes.

Methods and Results










- meta-analysis was performed using microarray data deposited at Oncomine.org
- host genes with statistically significant differential expression in tumor vs control (up and down) were identified
- differentially expressed genes in tumor sets relative to controls were filtered for 3'UTR enrichment in intronic miRNA recognition sequences
- molecular function analysis of target gene was performed using Gene Ontology at fatigo.org

Intronic miRNA targets are enriched in breast cancer










Intronic miRNA targets define tissue-specific molecular functions

























1. Alizadeh_lymphoma compared to Sorlie_breast

Molecular function	Percent enrichment	Study	p value
receptor activity	 8.52% 16.11%	lymphoma breast	0.04056
transmembrane receptor activity	 3.68% 11.94%	lymphoma breast	0.00771
hydrolase activity, acting on ester bonds	 8.59% 2.24%	lymphoma breast	0.02283
phosphoric ester hydrolase activity	 9.66% 1.77%	lymphoma breast	0.00897
transmembrane receptor protein kinase activi...	 0.69% 6.19%	lymphoma breast	0.02313
phosphoric monoester hydrolase activity	 11.82% 2.47%	lymphoma breast	0.02655
transmembrane receptor protein kinase activi...	 1.61% 21.88%	lymphoma breast	0.00197
phosphoprotein phosphatase activity	 20.97% 3.12%	lymphoma breast	0.02971
transmembrane receptor protein tyrosine kina...	 3.57% 36.84%	lymphoma breast	0.00473




2. Valk_leukemia compared to Sorlie_breast

Molecular function	Percent enrichment	Study	p value
ligase activity	 1.72% 6%	leukemia breast	0.01840
ligase activity, forming carbon-nitrogen bon...	 1.92% 6.62%	leukemia breast	0.01895
acid-amino acid ligase activity	 1.45% 7.63%	leukemia breast	0.00351
endopeptidase activity	 0.73% 5.08%	leukemia breast	0.01061
ubiquitin-protein ligase activity	 2.17% 10.71%	leukemia breast	0.00459
serine-type endopeptidase activity	 0 % 3.57%	leukemia breast	0.03004
transmembrane receptor protein tyrosine kina...	 10.77% 33.33%	leukemia breast	0.03557

3. Valk_leukemia compared to Alizadeh_lymphoma


Molecular function	Percent enrichment	Study	p value
receptor activity	 5.33%	leukemia	0.00139
	 15.53%	lymphoma	
phosphatase regulator activity	 2.67%	leukemia	0.00992
	 0 %	lymphoma	
protein binding	 51.33%	leukemia	0.03715
	 40.99%	lymphoma	
receptor binding	 6.67%	leukemia	0.03743
	 2.48%	lymphoma	
transmembrane receptor activity	 2.14%	leukemia	0.00107
	 11.15%	lymphoma	
protein phosphatase regulator activity	 2.86%	leukemia	0.01122
	 0 %	lymphoma	
hydrolase activity, acting on ester bonds	 10.71%	leukemia	0.03841
	 4.88%	lymphoma	
receptor binding	 7.14%	leukemia	0.04235
	 2.79%	lymphoma	
protein phosphatase type 2A regulator activi...	 3.15%	leukemia	0.01221
	 0 %	lymphoma	
protein heterodimerization activity	 3.15%	leukemia	0.01221
	 0 %	lymphoma	
phosphoric ester hydrolase activity	 11.81%	leukemia	0.02310
	 5.16%	lymphoma	
phosphoprotein phosphatase activity	 25.45%	leukemia	0.04148
	 11.83%	lymphoma	

Host gene and miRNA target correlation in Valk_leukemia




Gene set 1: Same transcription unit (34 genes)

- intronic miRNAs and host genes
- correlate host gene expression with expression of miRNA targets



Gene set 2: Different transcription unit (35 genes)



- non-intronic miRNA and upstream genes
- correlate upstream gene expression with expression of miRNA targets



Percentage of host genes that significantly correlate with miRNA target expression in the Valk_leukemia data set

Same transcription unit

Downstream transcription unit



Cluster analysis of clinical samples using host gene expression data

Background


- intronic miRNAs regulate expression of $\sim 1/3$ of all miRNA targets, or between 3 and 10% of all genes
- microarray data has shown a negative correlation between miRNA expression and that of target genes

Methods and Results

- normal karyotype clinical samples were extracted from the Valk-leukemia data set
- initial cluster analysis was performed using the entire gene set
- performance of cluster analysis based on host gene expression was compared to that of a random gene subset

NBM, CD34+ and clinical samples from Valk_leukemia are clustered by hostgene expression but not by of a random gene subset

Host gene subset



Random gene subset

